ValidCare is adding a second cohort of CBD brands to its large scale, human safety study, with additional financial support from Open Book Extracts.
ValidCare (Denver, CO) is adding a second cohort of CBD brands to its large scale, human safety study. ValidCare has already shared the results of its first cohort with the FDA, and has plans to study the results in a peer reviewed journal. The second cohort will enhance the reliability of its previous findings.
“We welcome the participation of industry-leading Garden of Life, as well as Impact Naturals, Tauriga Sciences, Inc. and others in this important industry led research,” said Keith Aqua, MD, co-principal investigator of this IRB approved study, in a press release. “The addition of this cohort strengthens the statistical reliability of the liver safety results as well as whether drowsiness or testosterone levels are impacted by long-term CBD consumption. All of these measures are important to FDA and consumers.”
ValidCare also has additional financial support from Open Book Extracts (OBX; Roxboro, NC), which is a manufacturer, distributor, and formulator cannabinoid ingredients and finished products. “As an ingredient manufacturer and product development house that helps brands bring safe and effective products to market, we are pleased to support this meaningful safety research that benefits our clients and the industry at large,” said Dave Neundorfer, CEO of OBX, in a press release. “OBX believes that this research is essential to optimize the targeted benefits of cannabinoids to consumers around the world.”